Literature DB >> 11861613

Genetic dissection of immunity to mycobacteria: the human model.

Jean-Laurent Casanova1, Laurent Abel.   

Abstract

Humans are exposed to a variety of environmental mycobacteria (EM), and most children are inoculated with live Bacille Calmette-Guérin (BCG) vaccine. In addition, most of the world's population is occasionally exposed to human-borne mycobacterial species, which are less abundant but more virulent. Although rarely pathogenic, mildly virulent mycobacteria, including BCG and most EM, may cause a variety of clinical diseases. Mycobacterium tuberculosis, M. leprae, and EM M. ulcerans are more virulent, causing tuberculosis, leprosy, and Buruli ulcer, respectively. Remarkably, only a minority of individuals develop clinical disease, even if infected with virulent mycobacteria. The interindividual variability of clinical outcome is thought to result in part from variability in the human genes that control host defense. In this well-defined microbiological and clinical context, the principles of mouse immunology and the methods of human genetics can be combined to facilitate the genetic dissection of immunity to mycobacteria. The natural infections are unique to the human model, not being found in any of the animal models of experimental infection. We review current genetic knowledge concerning the simple and complex inheritance of predisposition to mycobacterial diseases in humans. Rare patients with Mendelian disorders have been found to be vulnerable to BCG, a few EM, and M. tuberculosis. Most cases of presumed Mendelian susceptibility to these and other mycobacterial species remain unexplained. In the general population leprosy and tuberculosis have been shown to be associated with certain human genetic polymorphisms and linked to certain chromosomal regions. The causal vulnerability genes themselves have yet to be identified and their pathogenic alleles immunologically validated. The studies carried out to date have been fruitful, initiating the genetic dissection of protective immunity against a variety of mycobacterial species in natural conditions of infection. The human model has potential uses beyond the study of mycobacterial infections and may well become a model of choice for the investigation of immunity to infectious agents.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11861613     DOI: 10.1146/annurev.immunol.20.081501.125851

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  355 in total

1.  Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease.

Authors:  Jacinta Bustamante; Andres A Arias; Guillaume Vogt; Capucine Picard; Lizbeth Blancas Galicia; Carolina Prando; Audrey V Grant; Christophe C Marchal; Marjorie Hubeau; Ariane Chapgier; Ludovic de Beaucoudrey; Anne Puel; Jacqueline Feinberg; Ethan Valinetz; Lucile Jannière; Céline Besse; Anne Boland; Jean-Marie Brisseau; Stéphane Blanche; Olivier Lortholary; Claire Fieschi; Jean-François Emile; Stéphanie Boisson-Dupuis; Saleh Al-Muhsen; Bruce Woda; Peter E Newburger; Antonio Condino-Neto; Mary C Dinauer; Laurent Abel; Jean-Laurent Casanova
Journal:  Nat Immunol       Date:  2011-01-30       Impact factor: 25.606

Review 2.  Mycobacterium szulgai: an unusual cause of disseminated mycobacterial infections.

Authors:  S Riedel; K Dionne; C Ellis; A Duffield; K C Carroll; N M Parrish
Journal:  Infection       Date:  2011-10-29       Impact factor: 3.553

3.  Association study of the single nucleotide polymorphisms of PARK2 and PACRG with leprosy susceptibility in Chinese population.

Authors:  Jinghui Li; Hong Liu; Jian Liu; Xi'an Fu; Yongxiang Yu; Gongqi Yu; Shumin Chen; Tongsheng Chu; Nan Lu; Fangfang Bao; Chunying Yuan; Furen Zhang
Journal:  Eur J Hum Genet       Date:  2011-10-19       Impact factor: 4.246

4.  Human TOLLIP regulates TLR2 and TLR4 signaling and its polymorphisms are associated with susceptibility to tuberculosis.

Authors:  Javeed A Shah; Jay C Vary; Tran T H Chau; Nguyen D Bang; Nguyen T B Yen; Jeremy J Farrar; Sarah J Dunstan; Thomas R Hawn
Journal:  J Immunol       Date:  2012-07-09       Impact factor: 5.422

Review 5.  Averting inflammation by targeting the cytokine environment.

Authors:  Manfred Kopf; Martin F Bachmann; Benjamin J Marsland
Journal:  Nat Rev Drug Discov       Date:  2010-09       Impact factor: 84.694

Review 6.  Management of nontuberculous mycobacterial infection in the elderly.

Authors:  Mehdi Mirsaeidi; Maham Farshidpour; Golnaz Ebrahimi; Stefano Aliberti; Joseph O Falkinham
Journal:  Eur J Intern Med       Date:  2014-03-29       Impact factor: 4.487

7.  Bioluminescence imaging reveals systemic dissemination of herpes simplex virus type 1 in the absence of interferon receptors.

Authors:  Gary D Luker; Julie L Prior; Jiling Song; Christina M Pica; David A Leib
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Importance of T cells, gamma interferon, and tumor necrosis factor in immune control of the rapid grower Mycobacterium abscessus in C57BL/6 mice.

Authors:  Martin Rottman; Emilie Catherinot; Patrick Hochedez; Jean-François Emile; Jean-Laurent Casanova; Jean-Louis Gaillard; Claire Soudais
Journal:  Infect Immun       Date:  2007-09-17       Impact factor: 3.441

9.  Alleles of the NRAMP1 gene are risk factors for pediatric tuberculosis disease.

Authors:  Suneil Malik; Laurent Abel; Heather Tooker; Audrey Poon; Leah Simkin; Manon Girard; Gerald J Adams; Jeffrey R Starke; Kimberly C Smith; Edward A Graviss; James M Musser; Erwin Schurr
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-15       Impact factor: 11.205

10.  Heterozygosity for the Y701C STAT1 mutation in a multiplex kindred with multifocal osteomyelitis.

Authors:  Osamu Hirata; Satoshi Okada; Miyuki Tsumura; Reiko Kagawa; Mizuka Miki; Hiroshi Kawaguchi; Kazuhiro Nakamura; Stéphanie Boisson-Dupuis; Jean-Laurent Casanova; Yoshihiro Takihara; Masao Kobayashi
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.